DeepMed Research

The Sidney Kimmel Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Employees: -

Market Cap: -

Website: http://www.hopkinsmedicine.org/kimmel_cancer_center

Clinical Trials

Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Hodgkin's Disease

Interventions: Drug: I-131 Tositumomab therapeutic regimen

First Posted Date: 2007-06-11

Last Posted Date: 2018-08-01

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 12

Registration Number: NCT00484874

Locations: 🇺🇸
Johns Hopkins Medical Institutions, Baltimore, Maryland, United States

Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma

Phase 2

Terminated

Conditions: Refractory Nasopharyngeal Carcinoma

Interventions: Drug: Ifosfamide
Drug: Doxorubicin

First Posted Date: 2007-06-11

Last Posted Date: 2019-02-11

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 9

Registration Number: NCT00484601

Locations: 🇸🇬
Johns Hopkins Singapore International Medical Center, Singapore, Singapore

Making Decisions About Participating in a Cancer Clinical Trial for Patients With Stage II, Stage III, or Stage IV Pancreatic Cancer or Stage III or Stage IV Colon Cancer or Rectal Cancer

Not Applicable

Completed

Conditions: Colorectal Cancer
Pancreatic Cancer
Psychosocial Effects of Cancer and Its Treatment

First Posted Date: 2007-05-24

Last Posted Date: 2019-03-21

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 205

Registration Number: NCT00478010

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Vaccine Therapy in Treating Patients Who Have Received First-Line Therapy for Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Biological: Hodgkin's antigens-GM-CSF-expressing cell vaccine
Procedure: adjuvant therapy

First Posted Date: 2007-05-24

Last Posted Date: 2018-02-28

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 1

Registration Number: NCT00478062

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Pharmacokinetics in Patients With Newly Diagnosed High-Grade Glioma Receiving Temozolomide and Radiation Therapy

Terminated

Conditions: Brain and Central Nervous System Tumors
Thrombocytopenia

First Posted Date: 2007-05-10

Last Posted Date: 2018-07-09

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 10

Registration Number: NCT00471653

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant

Phase 1

Terminated

Conditions: Leukemia
Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2007-05-07

Last Posted Date: 2014-03-21

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 1

Registration Number: NCT00469820

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma

Early Phase 1

Terminated

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Biological: recombinant interferon-α
Biological: recombinant interleukin-6

First Posted Date: 2007-05-07

Last Posted Date: 2018-11-16

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 3

Registration Number: NCT00470093

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: Paclitaxel, Carboplatin and Irinotecan

First Posted Date: 2007-04-25

Last Posted Date: 2019-02-11

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 7

Registration Number: NCT00465907

Locations: 🇸🇬
Johns Hopkins Singapore International Medical Center, Singapore, Singapore

Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

First Posted Date: 2007-04-25

Last Posted Date: 2009-08-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 2

Registration Number: NCT00465673

Locations: 🇸🇬
Johns Hopkins Singapore International Medical Center, Singapore, Singapore

Protein Biomarker in Hepatocellular Carcinoma

Terminated

Conditions: Normal Volunteers
Liver Cirrhosis
Hepatitis
Hepatocellular Carcinoma

First Posted Date: 2007-04-25

Last Posted Date: 2019-02-15

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 211

Registration Number: NCT00465842

Locations: 🇸🇬
Johns Hopkins Singapore International Medical Center, Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy